Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From the National Marrow Donor Program
2007 NOV 19 -- The National Marrow Donor Program (NMDP) has selected an abstract written by Dr. Auayporn Nademanee, physician and professor in the Division of Hematology & Hematopoietic Cell Transplantation at City of Hope, and Dr. Robert Chow, Founder and Global Medical Director for StemCyte, as one of four best abstracts at its annual Council Meeting in Minneapolis, MN. The abstract, "Adult Patients with Malignancies Transplanted with Plasma Depleted Cord Blood (PD CB) -- A Retrospective Audited Analysis of 107 Patients" was presented by Dr. Nademanee at the NMDP Council Meeting and has several other co-authors. The abstract describes the safety and effectiveness of transplanting single or double plasma-depleted umbilical cord blood units into adult patients with cancers of the blood. All of the plasma-depleted cord blood was processed and shipped from the StemCyte International Cord Blood Center in Arcadia, CA. Dr. Nademanee says, "Patients treated with plasma-depleted cord blood demonstrated excellent outcomes in terms of overall survival, transplant-related mortality, and the absence of complications such as graft-versus-host disease. We believe that plasma-depleted cord blood will continue to be an effective treatment for patients with leukemia, lymphoma, and other malignant indications." Dr. Chow says, "We thank NMDP for selecting ours as one of their Best Abstracts. We are heartened to see the outstanding patient outcomes using StemCyte's plasma-depleted cord blood products. However, none of these results would be possible without the tremendous care given to patients by physicians like Dr. Nademanee at City of Hope. We are gratified to have the support and confidence of physicians at City of Hope and other leading transplant centers around the world." StemCyte has shipped cord blood products to over 140 of the leading transplant centers in 32 countries around the world. Keywords: Blood Products, Blood Transfusion, Cell Transplantation, Cord Blood, Graft-Versus-Host Disease, Hematology, Hematopoietic, Medical Device, Stem Cell Research, Transfusion Medicine, StemCyte Inc. This article was prepared by Hematology Week editors from staff and other reports. Copyright 2007, Hematology Week via NewsRx.com.
|
